Proton therapy training offered

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 4
Volume 17
Issue 4

Students at Ivy Tech Community College-Bloomington will be the first in the nation to be offered a specialized training program in proton therapy.

BLOOMINGTON, Indiana-Students at Ivy Tech Community College-Bloomington will be the first in the nation to be offered a specialized training program in proton therapy. The college has formed a partnership with ProCure Treatment Centers, Inc. to develop a certificate program that will train and credential students enrolled in the College’s Radiation Therapy program, with courses beginning next fall.

Everything but the protons


Procure’s Training and Development Center, located in Bloomington, celebrated its grand opening on March 27. The 20,000-square-foot center is the first facility in the world dedicated to proton therapy training, ProCure said in a media release. The facility offers before-the-job training that simulates all aspects of proton therapy in a replica of a proton therapy treatment center featuring everything but the actual protons.

Headquartered in Bloomington, ProCure Treatment Centers, Inc. was founded in 2005 by John Cameron, PhD, a particle therapy physics pioneer who was pivotal in the development of the Midwest Proton Therapy Institute in Bloomington. ProCure provides management support and a model for the complete design, construction, operation, and maintenance of proton centers.

Recent Videos
Based on its mechanism of action, anito-cel may cause fewer instances of cytokine release syndrome and delayed toxicities vs other therapies.
2 experts are featured in this series.
Once a patient-specific dose is determined, an all-oral combination of revumenib plus decitabine/cedazuridine and venetoclax may be “very good” in AML.
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Related Content